HCP Connect Clinical Author
Dr. Amit Desai
Endocrinology
Specialty
Endocrinology
Clinical Updates
26
Experience
9 Years
Author Biography
About Dr. Amit Desai
Dr. Amit Desai is an endocrinologist with 9 years of experience in metabolic medicine. He completed his DM in Endocrinology following an MD in General Medicine, with a focus on diabetes, thyroid disorders, and obesity. He takes particular interest in newer incretin-based and cardio-renal therapies. His articles turn dense endocrine trials into clear clinical takeaways.
Published Work
Recent Clinical Updates
26 articles
Endocrinology
FDA Approves denosumab-adet (Ponlimsi) as Interchangeable Biosimilar to Prolia
denosumab-adet (Ponlimsi) FDA approval March 2026: biosimilar/interchangeable to Prolia for osteoporosis; 60 mg SC every 6 months; REMS for severe hypocalcemia.
Endocrinology
Orforglipron (FOUNDAYO) FDA Approved for Obesity; 11.2% vs 2.1% Mean Weight Change in ATTAIN-1
orforglipron obesity: FDA approves FOUNDAYO (orforglipron) for adult chronic weight management; trials showed -11.2% vs -2.1% mean weight change at 72 weeks.
Endocrinology
GLP-1 Receptor Agonists Beyond Glycemia: Cardiovascular, Weight and Mechanistic Evidence for Clinicians
semaglutide cardiovascular risk reduction: mechanisms, indications, dosing, and safety from FDA labels, approvals, and peer-reviewed reviews.
Endocrinology
FDA Proposes 503B Exclusion for Semaglutide, Tirzepatide, Liraglutide
FDA proposes 503B bulks list exclusion for semaglutide, tirzepatide, liraglutide; semaglutide is a GLP-1 agonist indicated for T2DM and CV/renal risk reduction (semaglutide 503B co...
Endocrinology
FOUNDAYO Approved for Obesity; Oral Semaglutide −15.1% Weight Change in OASIS 1
Orforglipron (FOUNDAYO) approved for obesity in 2026; OASIS 1 oral semaglutide 50 mg showed −15.1% mean weight change vs −2.4% with placebo at week 68.
Endocrinology
FDA Approves orforglipron (FOUNDAYO) for Chronic Weight Management
orforglipron (FOUNDAYO) FDA approval for chronic weight management; ATTAIN-MAINTAIN showed superior maintenance of prior weight reduction vs placebo at 52 weeks.
Endocrinology
FDA Approves orforglipron for Weight Maintenance: 25.5% MBE
Orforglipron (FOUNDAYO) oral GLP-1 approved for weight maintenance; ATTAIN-MAINTAIN showed MBE treatment differences of 25.5% and 41.7% versus placebo.
Endocrinology
FDA Approves Insulin Icodec (Awiqli) for Type 2 Diabetes: 0.22% HbA1c Reduction in ONWARDS 3
insulin icodec type 2 diabetes: FDA approves Awiqli with -0.22% HbA1c reduction vs degludec in ONWARDS 3; weekly 70-unit dosing per label.
Endocrinology
FDA Approves Tirzepatide for Obesity: 20.9% Weight Loss in SURMOUNT-1
Tirzepatide (ZEPBOUND) FDA-approved for obesity; SURMOUNT-1 showed up to -20.9% mean weight loss at week 72 versus -3.1% with placebo — label 2023 approval.
Endocrinology
REDEFINE 1: CagriSema Achieves 20.4% Weight Loss in Adults
Cagrilintide semaglutide weight loss: REDEFINE 1 found −20.4% mean weight change vs −3.0% placebo at 68 weeks in adults with overweight or obesity.
Endocrinology
FDA Approves orforglipron for Obesity: 11.2% Weight Loss ATTAIN-1
orforglipron obesity: FOUNDAYO FDA approved 04/01/2026; ATTAIN-1 showed −11.2% vs −2.1% placebo weight change at 72 weeks in adults with obesity.
Endocrinology
Tirzepatide: Mounjaro vs Zepbound — Indications and Dosing Differences
Compare tirzepatide (MOUNJARO vs ZEPBOUND): labeled indications for T2DM vs weight reduction/OSA, initiation/escalation schedules, maintenance doses, and SURMOUNT-4 weight‑maintena...
Endocrinology
Insulin human (Afrezza): FDA Expands Indication to Ages ≥6
Insulin human (AFREZZA) label expanded May 2026 to include pediatric patients ≥6 yrs for glycemic control; labeling details dosing, pulmonary monitoring, and trial HbA1c data.
Endocrinology
FDA Approves Semaglutide for CV Risk in Obesity: SELECT Cuts MACE 20%
Semaglutide cardiovascular risk reduction: FDA approved Wegovy for adults with CV disease and obesity after SELECT showed a 20% MACE risk reduction.
Endocrinology
Exploring the Expanding Role of GLP-1 Receptor Agonists Beyond Diabetes Management
Discover the expanding roles of GLP-1 receptor agonists in obesity, cardiovascular health, and neuroprotection beyond diabetes management.
Medical Research
Identify 5 Overeating Types for Targeted Interventions
Wearable sensors track eating habits to inform personalized obesity care and tailored interventions for better patient outcomes.
Healthcare Business
Targeted AFib Screening: Improved Outcomes
Learn how targeted atrial fibrillation screening can improve patient outcomes and reduce unnecessary tests in your practice, despite controversy over mass screening.
Healthcare Business
Boost Rural Healthcare with $10B Annual Funding
Discover how to access $50 billion in federal funding to enhance rural healthcare, improve provider recruitment, and adopt innovative technology.
Healthcare Business
Medicare Pay Cuts: 2.5% Reimbursement Reduction Looms
Proposed 2026 Medicare pay changes may cut reimbursement by 2.5% for thousands of procedures, affecting doctor pay and practice expenses.
Medical Research
Cut Diabetic Retinopathy Risk by 30% with GLP-1 Therapy
New research suggests GLP-1 receptor agonist drugs like semaglutide can significantly reduce diabetic retinopathy risk, a common diabetes complication.
Digital Health
Cut Pre-Op Admin Time with Digital Forms
Streamline pre-operative assessments with digital forms, reducing admin burden and enhancing patient engagement through remote access.
Medical Research
Eczema Patients at 30% Higher Risk of Suicidal Thoughts
New study reveals atopic eczema patients face increased risk of suicidal ideation, identifying key factors driving this elevated risk for better patient care.
Medical Research
Stroke Recovery Boosted by 7-Day Neural Progenitor Cell Transplant
Discover how transplanting hiPSC-NPCs 7 days post-stroke leads to long-term graft survival and potential for improved patient outcomes in stroke recovery.
Wellness
Reduce Blood Clot Risk 30% with Simple Desk Habits
Learn how to minimize the risk of deadly blood clots with simple changes to your daily desk routine and recognize the signs of venous thromboembolism.
Pharmaceutical
Vaccine Access Updates: What Physicians Need to Know
Stay informed on potential changes to US immunization policy and vaccine access, and how it may impact your practice and patient care.
Medical Research
New Treatment Cuts Vision Loss in LHON Patients
Discover how a novel treatment for Leber's Hereditary Optic Neuropathy (LHON) can help prevent sudden vision loss in patients, now approved for NHS use.